Molecular Internal Medicine

Gender Medicine

GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases
M.R. Meyer, M. Barton

J Steroid Biochem Mol Biol 176, 82-87, 2018


Twenty years of G protein-coupled estrogen receptor GPER: historical and personal perspectives
M. Barton, E. J. Filardo, S.J. Lolait, P. Thomas, M. Maggiolini, E.R. Prossnitz
J Steroid Biochem Mol Biol 176, 4-15, 2018


Rapid vasodilation to raloxifene: role of estrogen receptors and off-target effects
M. Barton, E.R. Prossnitz.
Br J Pharmacol 174, 4201-4202, 2017


GPER mediates functional endothelial aging in renal arteries
M.R. Meyer, T. Rosemann, M. Barton, E.R. Prossnitz.
Pharmacology 100, 188-193, 2017



Obligatory role for GPER in cardiovascular aging and disease
M.R. Meyer, N.C. Fredette, C. Daniel, G. Sharma, K. Amann, J.B. Arterburn, M. Barton, E.R. Prossnitz.
Science Signaling 9, ra105, 2016


Estrogen signaling in the adrenal cortex: implications for blood pressure sex differences
B. Carrocia, T.M. Seccia, M. Barton, G.P. Rossi
Hypertension 68, 840-848, 2016


Estrogens and coronary artery disease: new clinical perspectives
M.R. Meyer, M. Barton
Adv Pharmacol 77, 307-360, 2016


Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER
M. Barton
Steroids 111, 37-35, 2016


GPER is required for the age-dependent upregulation of the myocardial endothelin system
M.R. Meyer, N.C. Fredette, G. Sharma, M. Barton, E.R. Prossnitz
Life Sci 159, 61-65, 2016



G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
J Endocrinol 227, 61-69, 2015


Erratum: G Protein-coupled estrogen receptor protects from atherosclerosis
M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Ammann, J.B. Arterburn, M. Barton, E.R. Prossnitz
Sci Rep 5, 13510, 2015


Nicolaus Copernicus and the rapid vascular responses to aldosterone
M. Barton, M.R. Meyer
Trends Endocrinol Metab 26, 396-398, 2015


Emerging roles of GPER in diabetes and atherosclerosis
M. Barton, E.R. Prossnitz
Trends Endocrinol Metab 26, 185-192, 2015


G Protein-coupled estrogen receptor protects from atherosclerosis
M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Ammann, J.B. Arterburn, M. Barton, E.R. Prossnitz.
Sci Rep 4, 7564, 2014


Estrogen biology: New insights on GPER function and clinical opportunities
E.R. Prossnitz, M. Barton
Mol Cell Endocrinol 389, 71-83, 2014


Alike but not the same: anatomic heterogeneity of estrogen receptor-mediated vasodilation
M. Barton, M.R. Meyer, E.R Prossnitz

J Cardiovasc Pharmacol 62, 22-25, 2013


Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013


Mechanisms and therapy of atherosclerosis and its clinical complications
M. Barton

Curr Opin Pharmacol 13, 149-153, 2013


Cholesterol and atherosclerosis: Modulation by estrogen
M. Barton

Curr Opin Lipidol 24, 214-220, 2013


Testosterone and secondary hypertension: New pieces to the puzzle
M. Barton, E.R. Prossnitz, M.R. Meyer

Hypertension 59, 1011-1103, 2012


Position paper: The membrane estrogen receptor GPER - clues and questions
M. Barton

Steroids 77, 925-242, 2012


Testosterone and secondary hypertension: New pieces to the puzzle
M. Barton, E.R. Prossnitz, M.R. Meyer

Hypertension 59, 1011-1103, 2012


GPER regulates endothelin-dependent vascular tone and intracellular calcium
M.R. Meyer, A.S. Field, N.L. Kanagy, M. Barton, E.R. Prossnitz
Life Sci 91, 623-627, 2012


Deletion of the G protein-coupled estrogen receptor increases endothelial vasoconstriction
M.R. Meyer, K. Amann, A.S. Field, C. Hu, H.J. Hathyway, N.L. Kanagy, M.K. Walker, M. Barton, E.R. Prossnitz

Hypertension 59, 507-512, 2012


The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function
M.R. Meyer, E.R. Prossnitz, M. Barton

Vascul Pharmacol 55, 17-25, 2011


The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton

Nature Rev Endocrinol 7, 715-726, 2011


Obesity, insulin resistance and diabetes: sex differences and role of estrogens receptors
M.R. Meyer, D.J. Clegg, E.R. Prossnitz, M. Barton
Acta Physiol (Oxf) 203, 259-269, 2011


GPER/GPR30 and regulation of vascular tone and blood pressure
M.R. Meyer, E.R. Prossnitz, M. Barton

Immunol Endocr Metab Agents Med Chem 4, 255-261, 2011


Estrogen-independent activation of estrogen receptors
M. Barton, M.R. Meyer, E.R. Prossnitz
Hypertension 57, 1056-1057, 2011


Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780
M.R. Meyer, O. Baretella, E.R. Prossnitz, M. Barton
Pharmacology 86, 58-64, 2010


Lung cancer and hormone replacement therapy
M. Barton, M.R. Meyer, J.L. Bolton, E.R. Prossnitz
Lancet 375, 117-118, 2010


ERα, ERβ, and gpER: novel aspects of estrogen receptor signaling in atherosclerosis
M.R. Meyer, M. Barton
Cardiovasc Res 83, 605-610, 2009


Postmenopausal hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension 54, 11-18, 2009
d


Non-genomic regulation of vascular cell function and growth by estrogen
M.R. Meyer, E. Haas, E.R. Prossnitz, M. Barton
Mol Cell Endocrinol 308, 9-16, 2009


Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER
E.R. Prossnitz, M. Barton
Prostaglandins Other Lipid Mediat 89, 89-97, 2009


Regulatory role of G protein coupled estrogen receptor for vascular function and obesity
E. Haas, I. Bhattacharya, E. Brailoiu, M. Damjanovic, G.C. Brailoiu, X. Gao, L. Mueller-Guerre, A. Gut, R. Minotti, M.R. Meyer,
K. Amann, E. Ammann, A. Perez-Dominguez, M. Genoni, D.J. Clegg, N.J. Dun, T.C. Resta, E.R. Prossnitz, M. Barton
Circ Res 104, 288-291, 2009


Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis
M.R. Meyer, E. Haas, M. Barton
Gend Med 5 (Suppl. A), S19-S33, 2008


Distinct roles of estrogen receptors α and β mediating acute vasodilatation of epicardial coronary arteries
T. Traupe, C.D. Stettler, H. Li, E. Haas, I. Bhattacharya, R. Minotti, M. Barton
Hypertension 49, 1364-1370, 2007


Differential effects of 17β-estradiol on function and expression of estrogen receptor α, estrogen receptor β, and GPR30 in arteries and veins of patients with atherosclerosis
E. Haas, M.R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti, H.H. Nguyen, A. Heigl, M. Lachat, M. Genoni, M. Barton
Hypertension 49, 1358-1363, 2007


WISDOM trial, postmenopausal hormone replacement and cardiovascular events: Why it is still not wise to use equine estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br Med J Rapid Response, e-pub August 28, 2007


Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler Thromb Vasc Biol 27, 1669-1672, 2007

Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling
M.R. Meyer, E. Haas, M. Barton
Hypertension 47, 1019-26, 2006

Postmenopausal hormone-replacement therapy
M. Barton, R.K. Dubey
N Engl J Med 346, 63-65, 2002

Acute effects of 17β-oestradiol on functional activity of endothelin-converting enzymes in human arteries and veins
A. Heigl, M. Lachat, T. Lattmann, T. Luscher, M. Barton
Clin Sci (Lond) 103(S), 438S-441S, 2002

Estrogen and apoptosis in atherosclerosis
M. Barton, M.M. Kockx
Midlife Health - Current Concepts and Challenges for the Future, Samioe G, Skouby S, (Eds.). Proceedings of the
5th European Congress on Menopause, Copenhagen, Denmark, July 1-5, 2000
Elsevier International Congress Series, 81-93, 2002


Postmenopausal estrogen replacement therapy and atherosclerosis: Can current compounds provide cardiovascular protection?
M. Barton
Exp Opin Invest Drugs 20, 789-809, 2001


Sex and NO - beyond regulation of vasomotor tone
M. Barton
Cardiovasc Res 46, 20-23, 2000


Estrogen and vascular resistance
M. Barton, T.F. Luscher
Curr Opin Endocrinol Diabet 6, 218-224, 1999


Vascular effects of estrogens: rapid actions, novel mechanisms, and potential therapeutic implications
M. Barton
Acta Pharmacol Sin 20, 682-690, 1999


Vascular effect of estrogen
E. Wight, M. Barton, E. Espinosa, T. Luscher.
In: Menopause and the Heart (T.B. Clarkson, P. Collins, Eds), Taylor & Francis, Philadelphia, 1, 1-7, 1999


17β-Estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries
M. Barton, J. Cremer, A. Mügge
Eur J Pharmacol 362, 73-76, 1998


Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17β-estradiol in human internal mammary arteries in vitro
A. Mügge, M. Barton, H.G. Fieguth, M. Riedel
Pharmacology 54, 162-168, 1997


Gefässprotektion durch Oestrogene. Wirkungen in vitro und in vivo - Mechanismen und klinische Implikationen
M. Barton, E. Wright, D.D. Do, Z. Yang, E. Espinosa, U. Arnet, T.F. Luscher
Schweiz Rundsch Med (PRAXIS) 86, 129-137, 1997


17β-Oestradiol inhibits growth of human vascular smooth muscle: similar effects in cells from females and males
Z. Yang, D.D. Do, E. Espinosa, M. Barton, A. Arnet, T. F. Luscher
J Cardiovasc Pharmacol 28 (Suppl. 5), S34-S39, 1996


Wirkungen natürlicher Oestrogene auf die Gefässwand: Molekulare Mechanismen und klinische Implikationen
T.F. Luscher, M. Barton, E. Wight, E. Espinosa, Z. Yang
Schweiz Med Wschr 126, 1748-1755, 1996


Endothelium-independent relaxation by 17β-oestradiol of human coronary arteries in vitro
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Cardiovasc Res 27, 1939-1942, 1993


17β-Oestradiol dilates both human internal and coronary arteries by an endothelium-independent mechanism.
M. Barton, M. Riedel, A. Mügge
Naunyn-Schmiedeberg's Arch Pharmacol 347, 43, 1993